OBJECTIVE: : To determine predictors of loss to follow-up (LTFU) in trials of candidate HIV vaccines. METHODS: : Data were obtained from trials of candidate preventive HIV vaccines conducted by the AIDS Vaccine Evaluation Group (AVEG) and HIV Network for Prevention Trials (HIVNET) that enrolled HIV-negative volunteers. Analytic models included multiple logistic regression and generalized estimating equations. RESULTS: : Of 3033 volunteers enrolled in 48 trials, 282 (9.3%) persons did not complete follow-up. In univariate analyses, age, trial duration, and number of immunizations were associated with LTFU. In a multivariate logistic model, age (per year) (adjusted odds ratio [AOR] = 0.96, 95% confidence interval [CI]: 0.95, 0.98) and study duration (per month) (AOR = 1.04, 95% CI: 1.01, 1.08) remained significantly associated with LTFU. CONCLUSIONS: : Younger age and increasing trial duration predicted LTFU. Limiting enrollment in trials of novel products to those less than 40 years of age may exclude participants shown to have improved retention. Trials should be designed to last only as long as required to address the scientific question. Retention efforts in future trials should especially address younger persons.
OBJECTIVE: : To determine predictors of loss to follow-up (LTFU) in trials of candidate HIV vaccines. METHODS: : Data were obtained from trials of candidate preventive HIV vaccines conducted by the AIDS Vaccine Evaluation Group (AVEG) and HIV Network for Prevention Trials (HIVNET) that enrolled HIV-negative volunteers. Analytic models included multiple logistic regression and generalized estimating equations. RESULTS: : Of 3033 volunteers enrolled in 48 trials, 282 (9.3%) persons did not complete follow-up. In univariate analyses, age, trial duration, and number of immunizations were associated with LTFU. In a multivariate logistic model, age (per year) (adjusted odds ratio [AOR] = 0.96, 95% confidence interval [CI]: 0.95, 0.98) and study duration (per month) (AOR = 1.04, 95% CI: 1.01, 1.08) remained significantly associated with LTFU. CONCLUSIONS: : Younger age and increasing trial duration predicted LTFU. Limiting enrollment in trials of novel products to those less than 40 years of age may exclude participants shown to have improved retention. Trials should be designed to last only as long as required to address the scientific question. Retention efforts in future trials should especially address younger persons.
Authors: Alice J Sheffet; Jenifer H Voeks; Ariane Mackey; William Brooks; Wayne M Clark; Michael D Hill; Virginia J Howard; Susan E Hughes; MeeLee Tom; Mary E Longbottom; Thomas G Brott Journal: Clin Trials Date: 2015-06-29 Impact factor: 2.486
Authors: Rebecca Giguere; Gregory D Zimet; Jessica A Kahn; Curtis Dolezal; Cheng-Shiun Leu; Marina Mabragaña; Ian McGowan; Alex Carballo-Diéguez Journal: World J AIDS Date: 2013-09
Authors: Paige L Williams; Russell Van Dyke; Michelle Eagle; Dorothy Smith; Carol Vincent; Gregory Ciupak; James Oleske; George R Seage Journal: Am J Epidemiol Date: 2008-04-15 Impact factor: 4.897
Authors: Paula M Frew; Carlos del Rio; Lu Lu; Sarah Clifton; Mark J Mulligan Journal: J Acquir Immune Defic Syndr Date: 2009-03-01 Impact factor: 3.731
Authors: N Jeanne Conley; Patricia B Pavlinac; Brandon L Guthrie; Romel D Mackelprang; Anthony N Muiru; Robert Y Choi; Rose Bosire; Ann Gatuguta; Carey Farquhar Journal: PLoS One Date: 2012-08-21 Impact factor: 3.240